Anupam Rasayan India shareholders approved a Rs 1.5 per share dividend at the company's 23rd AGM. The firm reported a 64.6% jump in revenue to Rs 2,384 crore for FY26, signaling a pivot toward operational efficiency after a period of rapid capacity expansion.
Anupam Rasayan FY26 Results and AGM Updates
Revenue grew 64.6% to Rs 2,384 crore, while Profit After Tax rose 38.8% to Rs 222 crore.
Reader Takeaway: Strong revenue growth and strategic acquisitions drive expansion, with a shift toward operational efficiency in FY27.
What just happened
Anupam Rasayan concluded its 23rd Annual General Meeting on September 30, 2026, where shareholders formally adopted the audited financial statements for FY26. Investors approved a final dividend of Rs 1.5 per share (15% of face value). The meeting also saw the reappointment of Mr. Anand Sureshbhai Desai as a Director.
Why this matters
The company confirmed an unqualified audit report, providing clarity on its financial health. The move from massive capital expenditure to operational efficiency signals a maturation phase, focusing on utilizing existing assets rather than aggressive capacity building. The company’s successful integration of Jayhawk Fine Chemicals and its stake in Bliss GVS Pharma remains a core component of its growth narrative.
Business Performance
Revenue distribution remains well-diversified, with Agro contributing 55%, Pharma 20%, Performance Materials 18%, and Personal Care 7%. The firm now manages over 125 products, supported by a pipeline of 90+ molecules. Sustainability efforts are also noteworthy, with 60.35% of power usage now derived from renewable energy, aiming for net-zero by 2027.
What to track next
Investors should monitor the company's working capital management and the scaling of commercialized products as management pivots its focus toward asset utilization and margin improvement.